AzTrials
AzTrials

Metabolic DisturbancePAH-ProMetGenNCT05679544

Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs

A study testing Characterization of early biological effects following exposure to PAHs in people with Metabolic Disturbance and Protein Deficiency, run by University Hospital, Grenoble at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This research project aims at better understanding the early biological effects resulting from occupational exposure to complex Polycyclic Aromatic Hydrocarbon (PAH) mixtures. Current biomarkers used as part of biomonitoring campaigns are biomarkers of exposure, not numerous and poorly related to health effects. Read more about this study

Who is it for?
Ages 18 years and older, men onlyHealthy volunteers can take part
What is being tested?
Characterization of early biological effects following exposure to PAHs
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteFrance
Study dates
25 Apr 2023to Oct 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Subjects ages 18 years or more
  • Subjects occupationally exposed to PAHs since more than 3 months
  • Having signed the informed consent
  • recruited by the occupational health service

Who cannot join

  • Obesity (BMI>30)
  • Subjects suffering cancers or metabolic diseases (diabetes, dyslipidemia, amino-acid diseases, renal or hepatic impairment) at the onset of the study.
  • Subjects taking medications related to the above diseases at the onset of the study.

Trial locations and contacts

1 site in 1 country.

France1 site, 1 recruiting
  • CHU Grenoble Alpes

    Grenoble, 38043

    Renaud Persoons, 04 76 76 51 78, RPersoons@chu-grenoble.fr

    Christine Demeilliers, 04 76 63 75 01, christine.demeilliers@univ-grenoble-alpes.fr

    Recruiting

Other trials in France

About this study

Official title: Biological Signatures (Proteomics, Metabolomics and Genotoxicity) Associated With Occupational Exposure to PAH Mixtures and Relation With Exposure Biomarkers: Support for the Derivation of Biological Limit Values

This research project aims at better understanding the early biological effects resulting from occupational exposure to complex Polycyclic Aromatic Hydrocarbon (PAH) mixtures.

Current biomarkers used as part of biomonitoring campaigns are biomarkers of exposure, not numerous and poorly related to health effects.

The aim of this study is thus to improve our understanding of biological consequences of such exposures, both in terms of proteins deregulation, metabolism deregulation and genotoxicity.

Read the detailed description

PAHs are ubiquitous pollutants inducing several diseases, among which cancer is the most significant endpoint, with increased incidences of lung, skin, and bladder cancers. PAHs induce genotoxic effects (sister chromatids exchange, micronuclei, DNA damage) but require metabolic activation in humans as indirect-acting carcinogens. Thus, the knowledge of metabolic pathways involved following PAH exposure is critical for understanding and preventing cancer risks. Besides, exposure to PAHs is assumed to induce other adverse health effects (diabetes, inflammation, infertility, cardiovascular disease). Unfortunately, early disease-related biomarkers are still largely unknown and our comprehension about the mechanisms involved is still limited. The rare existing biological limit values either refer to not carcinogenic PAH (pyrene) or detoxification pathways (3-OHBaP for BaP), although new biomarkers reflecting the genotoxic pathway of BaP (TetraolBaP) are now available. There is thus a need for identifying more relevant biomarkers of exposure / effect, and for a better understanding of the biological consequences resulting from PAH exposures as well as the associated metabolic pathways involved.

The objectives of the project are :

  • To better understand and characterize molecular, metabolic and genotoxic impacts resulting from exposure to PAHs and to link such impacts with biological levels of various PAH metabolites,
  • To study the influence of BaP metabolism (genotoxic versus detoxication pathway) on the differential expression of metabolites / proteins and on genotoxicity endpoints in order to get relevant data for deriving new biological limit values,
  • To elucidate the associations between omics deregulations due to PAH exposures and activated metabolic pathways, in order to define candidate effect biomarkers for human biomonitoring.

The originalities of the project are the following. First, this is a human study performed in real occupational settings on workers exposed to representative PAH mixtures. It is a multidisciplinary approach simultaneously combining up-to-date biomonitoring, omics and cytogenetics analyses, that will give insight into a comprehensive view of metabolic reactions and protein expressions following occupational exposure to PAH mixtures, and allow the identification of the biological processes involved. Carcinogenic BaP metabolites (Tetraol-BaP and 3-OHBaP) will be simultaneously analyzed in order to compare the two main metabolic pathways of BaP.

The main steps of the projects will be :

  • Recruitment of 100 workers differentially exposed to PAH mixtures sampled across two time periods (after weeks of exposure and following 3 weeks without occupational exposure),
  • Recording of relevant data (work characteristics, jobs / tasks, working experience, number of years of exposure, smoking habits, nutritional intake, co-morbidity),
  • Toxicological analyses (LC-Fluorescence and GC-MS-MS) of urinary metabolites of several gaseous and particulate PAHs (Naphtalene, Fluorene, Phenanthrene, Pyrene, BaP, BeP, Chrysene, Benzo(b)Fluoranthene, Benzo(k)Fluoranthene, Benzo(a)Anthracene),
  • Proteomics analyses on blood samples through an enrichment approach for a bottom-up label free quantitative proteomic analysis based LC-HR-MS. Deregulated proteins (DEP) will be identified and the associated protein signature. A gene ontology (GO) analysis will define the groups of biological processes involved,
  • Untargeted Metabolomics analyses on blood samples in UHPLC-HR-MS, with unsupervised statistical analyses (Principal Component Analysis, Logistic Regressions), identification of relevant metabolites by their comparison to the Human Metabolome database, and advanced molecular networking / spectral library search of LC-MSMS data,
  • Micronuclei (MN) in buccal cells through the harvesting of buccal cells using a cytobrush, transfer to the lab in a buffer, fixing and staining, automatic counting under fluorescent light.
Being tested
Characterization of early biological effects following exposure to PAHs
Keywords
polycyclic aromatic hydrocarbons, metabolism, mixtures, occupational exposure, genotoxicity
Medical subject headings
Protein Deficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Characterization of early biological effects following exposure to PAHsBiological

    Biological samples collected in period of exposure and after holidays

Study groups in NCT05679544
Study groupRoleWhat they receive
Subjects occupationally exposed to PAHsExperimentalNot described
Receives: Biological: Characterization of early biological effects following exposure to PAHs

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Deregulation of blood proteins expression due to exposure to PAHs

    Number of proteins up or down regulated in period of exposure versus after holidays

    Measured: up to 6 months between both periods of study

  2. Deregulation of blood metabolites expression due to exposure to PAHs

    Number of metabolites up or down regulated in period of exposure versus after holidays

    Measured: up to 6 months between both periods of study

  3. Frequency of micronuclei measured due to exposure to PAHs

    Frequency of cells containing micronuclei in period of exposure versus after holidays

    Measured: up to 6 months between both periods of study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jan 2023
  2. Study start25 Apr 2023
  3. Primary completionOct 2025 (estimated)
  4. Study completionOct 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05679544
Sponsor's protocol ID
38RC22.0219
Other IDs
2022-A01590-43
Acronym
PAH-ProMetGen
Status last verified
May 2024
First submitted
23 Dec 2022
Last updated
3 Jun 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Characterization of early biological effects following exposure to PAHs in people with Metabolic Disturbance and Protein Deficiency, run by University Hospital, Grenoble at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 3 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Renaud PERSOONS, PhD, Pharm D (00 33 4 76 76 51 78, RPersoons@chu-grenoble.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Deregulation of blood proteins expression due to exposure to PAHs (time frame: up to 6 months between both periods of study). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in